Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Core Insights - The Chief Scientific Officer of Enliven Therapeutics sold 20,000 shares amid a significant stock price increase of 71% in January 2026 [1][5] - The transaction was valued at approximately $535,100, with the shares sold being part of a pre-arranged trading plan [2][7] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly leveraging small molecule drug design [4] - The company has a market capitalization of $1.57 billion and employs 65 people [3] Financial Performance - Enliven Therapeutics reported a net income loss of $97.21 million over the trailing twelve months [3] - The stock price increased by 26.75% over the past year as of January 20, 2026 [3] Recent Developments - The company announced positive initial data from early trials of ELVN-001, a leukemia treatment, contributing to the stock's performance [5] - Enliven aims to advance to phase three of clinical trials for ELVN-001 and is preparing to work with the FDA [6] Investor Considerations - The recent stock performance is closely tied to the progress of the leukemia treatment project, suggesting that investors should monitor FDA approval developments [8]